GFP Reporter Stable Cell Line-HeLa

High-risk human papillomavirus (HPV) infections not only cause cervical cancer, but have also been linked to the development of anogenital cancers as well as head and neck cancers. Researchers combined HPV E6/E7 siRNA with chemotherapeutic agents to analyze their synergistic effects in TP53 and RB/E2F signaling, cell proliferation and apoptosis. Through in vitro and in vivo experiments, it was found that the combination of E6/E7 siRNA and cisplatin restored TP53 and RB/E2F signaling more effectively than E6/E7 siRNA alone and led to apoptosis or cell cycle arrest. The researchers also developed a cellular kinetic model incorporating TP53-RB/E2F dynamics and cell proliferation characteristics, validating its utility in studying the E6/E7 siRNA combination treatment regimen. The interaction between TP53 and RB/E2F signaling mechanisms was further confirmed using a dual reporter system. Ultimately, by injecting BALB/c nude mice with E6/E7 siRNA cationic liposomes combined with cisplatin and paclitaxel, the researchers found that this combination therapy significantly inhibited tumor growth. In summary, the combination of E6/E7 siRNA and low-dose chemotherapy can effectively inhibit tumor growth by stabilizing TP53 and the RB/E2F inhibitory complex.

Figure 1. Researchers evaluated the growth characteristics and TP53 recovery of TP53-RE-GFP-stabilized cells transfected with HPV E6/E7 siRNA or control siRNA using the IncuCyte HD System (Essen Instruments, Ann Arbor, MI). Detailed setup procedures are listed in Supplementary Materials and Methods. Researchers analyzed TP53-RE-GFP dynamic time series in TP53-RE-GFP reporter HeLa stable cells treated with NC plus cisplatin (CDDP), SP, or SP plus CDDP. (Rajasekaran N, et al., 2017)